FDA approves Dupixent as add-on treatment for moderate-to-severe asthma – Sanofi + Regeneron

The FDA has approved Dupixent (dupilumab), from Sanofi + Regeneron, as an add-on maintenance treatment of patients aged 6 to 11 years with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma. The FDA approval is based on data from a Phase III randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of Dupixent combined with […]